OSUCCC—James study suggests a way to re-energize tired T cells when treating cancer, viral infections

OSU—James Immunotherapy Management Clinic to focus on managing immune side effects and cancer control

A clinic at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Pelotonia Immuno-Oncology Institute aims to help manage the autoimmune side effects of immunotherapy-based cancer treatment and allow patients to live the fullest life possible both during cancer treatment and long-term as a survivor.

April 12, 2024

Vol.50 No.15

Clinical Roundup

AI harnesses tumor genetics to predict treatment response

Scientists at University of California San Diego School of Medicine used a machine learning algorithm to predict when cancer will resist chemotherapy.

January 19, 2024

Vol.50 No.03

Clinical Roundup

Epigenomic platform may predict NSCLC immunotherapy response using liquid biopsies

Data published in The Journal for ImmunoTherapy of Cancer show ClearNote Health’s epigenomic platform may provide a novel tissue-free, liquid biopsy-based approach for prediction and monitoring of immunotherapy response for non-small cell lung cancer patients.

January 19, 2024

Vol.50 No.03

In Brief

Nationwide Children’s Hospital and OSUCCC—James open proton therapy center opens

Nationwide Children’s Hospital and The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute opened a $100 million, 55,000 square foot proton therapy center. It is the first treatment facility in central Ohio offering this highly targeted form of radiation therapy for treatment of complex tumors that cannot be removed through surgery.

January 05, 2024

Vol.50 No.01

In Brief

Matthew Ringel, Electra Paskett, Zihai Li named deputy directors at OSUCCC

Matthew RingelElectra PaskettZihai LiMatthew Ringel, Electra Paskett, and Zihai Li were named deputy directors at The Ohio State University Comprehensive Cancer Center. They will report to OSUCCC Director Raphael Pollock.

December 15, 2023

Vol.49 No.46

Clinical Roundup

Lung cancer study finds new target for treatment resistance after EGFR inhibitors

Researchers at MD Anderson Cancer Center have identified CD70 as being highly expressed on drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer, highlighting a novel therapeutic target that could be used to eliminate resistant cells remaining after treatment with commonly used EGFR tyrosine kinase inhibitors. The study was published in Cancer Cell.

February 17, 2023

Vol.49 No.07

OSUCCC—James study suggests a way to re-energize tired T cells when treating cancer, viral infections

YOU MAY BE INTERESTED IN

OSU—James Immunotherapy Management Clinic to focus on managing immune side effects and cancer control

AI harnesses tumor genetics to predict treatment response

Epigenomic platform may predict NSCLC immunotherapy response using liquid biopsies

Nationwide Children’s Hospital and OSUCCC—James open proton therapy center opens

Matthew Ringel, Electra Paskett, Zihai Li named deputy directors at OSUCCC

Lung cancer study finds new target for treatment resistance after EGFR inhibitors

Renew today!

Subscriber content

Login